A U.S. drug distribution company charged Canada’s Biovail Corp. and Britain’s GlaxoSmithKline with violations of antitrust laws in a suit filed in Boston federal court yesterday.
American Sales Co., of Erie, N.Y., charged in papers filed in U.S. District Court that Biovail and Glaxo filed “baseless” patent-infringement lawsuits and petitions with U.S. regulatory authorities to block generic competitors to a branded antidepressant drug from coming to market.
It charges that Biovail and Glaxo “engaged in sham litigation and petitioning and entered into anti-competitive agreements to improperly maintain their monopoly profits” for the drug, sold under the brand name Wellbutrin XL. It also claims the companies entered into agreements with developers of generic competitors to delay their entry into the market.